0.88
-0.0624(-6.64%)
Currency In USD
| Previous Close | 0.94 |
| Open | 0.94 |
| Day High | 0.95 |
| Day Low | 0.84 |
| 52-Week High | 2.43 |
| 52-Week Low | 0.66 |
| Volume | 1.95M |
| Average Volume | 1.41M |
| Market Cap | 101.77M |
| PE | 2 |
| EPS | 0.44 |
| Moving Average 50 Days | 0.83 |
| Moving Average 200 Days | 1.03 |
| Change | -0.06 |
If you invested $1000 in Coherus BioSciences, Inc. (CHRS) 10 years ago, it would be worth $25.06 as of August 02, 2025 at a share price of $0.878. Whereas If you bought $1000 worth of Coherus BioSciences, Inc. (CHRS) shares 5 years ago, it would be worth $48.15 as of August 02, 2025 at a share price of $0.878.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
GlobeNewswire Inc.
Jul 31, 2025 8:45 PM GMT
REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday,
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
GlobeNewswire Inc.
May 30, 2025 12:00 PM GMT
REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
GlobeNewswire Inc.
May 27, 2025 12:30 PM GMT
– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor –REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: